Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19646227 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAL3MBTL1KDM4ECFTR | |
| SCHEMBL18427396 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAL3MBTL1KDM4ECFTR | |
| SCHEMBL15316715 | 0.75 | HMGCR (0.35) | KDM4ECBLBKCNH2 | |
| SCHEMBL21012060 | 0.75 | ALDH1A1 (0.38) | SMN1; SMN2L3MBTL1KDM4ECFTRSLC6A2 | |
| SCHEMBL18522503 | 0.75 | ALDH1A1 (0.38) | SMN1; SMN2L3MBTL1KDM4ECFTRSLC6A2 | |
| SCHEMBL24467923 | 0.73 | ALDH1A1 (0.38) | LMNAKDM4ECFTRSLC6A2SLC6A4 | |
| SCHEMBL26042044 | 0.72 | KIF11 (0.49) | SMN1; SMN2LMNAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL19954875 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAL3MBTL1KDM4ESLC6A2 | |
| SCHEMBL21653566 | 0.72 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAL3MBTL1KDM4ECFTR | |
| SCHEMBL20079669 | 0.71 | CYP19A1 (0.40) | LMNAKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073478-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2022-03-10 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | SMN1; SMN2 129/4885LMNA 819/4885L3MBTL1 3959/4885 |
| US-20220073478-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | SMN1; SMN2 1680/4885LMNA 645/4885L3MBTL1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.